Sepsis
Researchers have developed a device that filters the protein galectin-3 from the blood, showing improved survival in rat and pig models of sepsis. The approach, tested by a team in China, reduced mortality compared to controls. Human trials are planned for 2027.
Von KI berichtet
Researchers from Australia have reported positive results from a Phase II clinical trial of a new carbohydrate-based drug for treating sepsis. The trial, involving 180 patients in China, demonstrated the drug's ability to reduce the condition's severity. This development offers hope for the first targeted therapy against a leading cause of global deaths.